Blockchain Registration Transaction Record

ADAP Advocacy Urges HRSA to Scrap Flawed 340B Rebate Pilot Program

ADAP Advocacy urges HRSA to abandon flawed 340B rebate pilot, citing ADAPs' 27-year success with rebate model. Hospitals receive 87% benefits but provide minimal charity care.

This news matters because the 340B Drug Pricing Program affects healthcare accessibility for vulnerable populations, particularly those living with HIV/AIDS. The program's integrity directly impacts prescription drug affordability and the quality of care for millions of Americans. When hospitals profit excessively from 340B benefits while providing minimal charity care, it undermines the program's original mission of helping low-income and uninsured patients. The proven success of ADAPs' rebate model demonstrates that efficient systems already exist to ensure program funds actually reach patients in need. This debate affects healthcare costs, drug pricing transparency, and ultimately determines whether safety-net programs fulfill their intended purpose of serving as a true payor of last resort for America's most vulnerable populations.